Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Myozyme in Late-Onset Pompe Disease
NCT00158600Phase 3Completed
- Sponsor
- Sanofi
- Start
- Sep 2005
- Primary completion
- Sep 2007
- Modality
- Replacement Enzymes
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in Pompe disease comparing alglucosidase alfa with Placebo (2 arms). Primary endpoints: Summary of Patients Reporting Treatment-Emergent Adverse Events, Mean Distance Walked as Measured by Six-minute Walk Test at Week 78 and 4 more. Started Sep 2005; status: completed.
02
Drugs
alglucosidase alfa
03
Conditions
Pompe disease
Beyond the preview
Go deeper on NCT00158600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00158600.